{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:09:36Z","timestamp":1774069776812,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Kinase inhibitors hold great potential as targeted therapy against malignant cells. Among them, the tyrosine kinase inhibitor dasatinib is known for a number of clinically relevant off-target actions, attributed in part to effects on components of the immune system, especially conventional T-cells and natural killer (NK)-cells. Here, we have hypothesized that dasatinib also influences non-conventional T-\u03b1\u03b2 cell subsets known for their potential anti-tumoral properties, namely iNKT cells and the distinct new innate CD8 T-cell subset. In mice, where the two subsets were originally characterized, an activated state of iNKT cells associated with a shift toward an iNKT cell Th1-phenotype was observed after dasatinib treatment <jats:italic>in vivo<\/jats:italic>. Despite decreased frequency of the total memory CD8 T-cell compartment, the proportion of innate-memory CD8 T-cells and their IFN\u03b3 expression in response to an innate-like stimulation increased in response to dasatinib. Lastly, in patients administered with dasatinib for the treatment of BCR-ABL-positive leukemias, we provided the proof of concept that the kinase inhibitor also influences the two innate T-cell subsets in humans, as attested by their increased frequency in the peripheral blood. These data highlight the potential immunostimulatory capacity of dasatinib on innate T-\u03b1\u03b2 cells, thereby opening new opportunities for chemoimmunotherapy.<\/jats:p>","DOI":"10.1038\/s41598-020-60195-z","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T11:07:31Z","timestamp":1582542451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Innate T-\u03b1\u03b2 lymphocytes as new immunological components of anti-tumoral \u201coff-target\u201d effects of the tyrosine kinase inhibitor dasatinib"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-065X","authenticated-orcid":false,"given":"Alice","family":"Barbarin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Piccirilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Cayssials","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Gombert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Herbelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"60195_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"P Wu","year":"2015","unstructured":"Wu, P., Nielsen, T. E. & Clausen, M. H. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36, 422\u2013439 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"60195_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","volume":"13","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M. & Kroemer, G. Immunological off-target effects of imatinib. Nat. Rev. Clin. Oncol. 13, 431\u2013446 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"60195_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035\u20131044 (2007).","journal-title":"Nat. Biotechnol."},{"key":"60195_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ctrv.2010.02.015","volume":"36","author":"J Araujo","year":"2010","unstructured":"Araujo, J. & Logothetis, C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat. Rev. 36, 492\u2013500 (2010).","journal-title":"Cancer Treat. Rev."},{"key":"60195_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","volume":"127","author":"S Blake","year":"2008","unstructured":"Blake, S., Hughes, T. P., Mayrhofer, G. & Lyons, A. B. The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin. Immunol. Orlando Fla 127, 330\u2013339 (2008).","journal-title":"Clin. Immunol. Orlando Fla"},{"key":"60195_CR6","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman, A. et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25, 1587\u20131597 (2011).","journal-title":"Leukemia"},{"key":"60195_CR7","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","volume":"111","author":"AE Schade","year":"2008","unstructured":"Schade, A. E. et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 111, 1366\u20131377 (2008).","journal-title":"Blood"},{"key":"60195_CR8","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.25233","volume":"127","author":"J Salih","year":"2010","unstructured":"Salih, J. et al. The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int. J. Cancer 127, 2119\u20132128 (2010).","journal-title":"Int. J. Cancer"},{"key":"60195_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.exphem.2008.09.013","volume":"37","author":"CK Fraser","year":"2009","unstructured":"Fraser, C. K. et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol. 37, 256\u2013265 (2009).","journal-title":"Exp. Hematol."},{"key":"60195_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/2326-6066.CIR-16-0061-T","volume":"5","author":"C Hekim","year":"2017","unstructured":"Hekim, C. et al. Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunol. Res. 5, 157\u2013169 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"60195_CR11","doi-asserted-by":"publisher","unstructured":"Wei, X., He, L., Wang, X., Lin, M. & Dai, J. Effects of dasatinib on CD8+T, Th1, and Treg cells in patients with chronic myeloid leukemia. J. Int. Med. Res. 300060519877321 https:\/\/doi.org\/10.1177\/0300060519877321 (2019).","DOI":"10.1177\/0300060519877321"},{"key":"60195_CR12","doi-asserted-by":"publisher","first-page":"e28925","DOI":"10.4161\/onci.28925","volume":"3","author":"A Kreutzman","year":"2014","unstructured":"Kreutzman, A., Ilander, M., Porkka, K., Vakkila, J. & Mustjoki, S. Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology 3, e28925 (2014).","journal-title":"Oncoimmunology"},{"key":"60195_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/leu.2013.221","volume":"28","author":"KN Wu","year":"2014","unstructured":"Wu, K. N. et al. Dasatinib promotes the potential of proliferation and antitumor responses of human \u03b3\u03b4T cells in a long-term induction ex vivo environment. Leukemia 28, 206\u2013210 (2014).","journal-title":"Leukemia"},{"key":"60195_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki, S. et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27, 914\u2013924 (2013).","journal-title":"Leukemia"},{"key":"60195_CR15","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki, S. et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23, 1398\u20131405 (2009).","journal-title":"Leukemia"},{"key":"60195_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s12185-012-1132-8","volume":"96","author":"H Tanaka","year":"2012","unstructured":"Tanaka, H., Nakashima, S. & Usuda, M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int. J. Hematol. 96, 308\u2013319 (2012).","journal-title":"Int. J. Hematol."},{"key":"60195_CR17","doi-asserted-by":"publisher","first-page":"E916","DOI":"10.1002\/ijc.27537","volume":"131","author":"N Hassold","year":"2012","unstructured":"Hassold, N. et al. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int. J. Cancer 131, E916\u2013927 (2012).","journal-title":"Int. J. Cancer"},{"key":"60195_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/hon.2034","volume":"31","author":"T Uchiyama","year":"2013","unstructured":"Uchiyama, T. et al. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study. Hematol. Oncol. 31, 156\u2013163 (2013).","journal-title":"Hematol. Oncol."},{"key":"60195_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","volume":"66","author":"Y Najima","year":"2018","unstructured":"Najima, Y. et al. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. Leuk. Res. 66, 66\u201372 (2018).","journal-title":"Leuk. Res."},{"key":"60195_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2018.02.014","volume":"68","author":"N Iriyama","year":"2018","unstructured":"Iriyama, N. et al. Enhanced perforin expression associated with dasatinib therapy in natural killer cells. Leuk. Res. 68, 1\u20138 (2018).","journal-title":"Leuk. Res."},{"key":"60195_CR21","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.3389\/fimmu.2018.03152","volume":"9","author":"M-C Chang","year":"2018","unstructured":"Chang, M.-C. et al. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. Front. Immunol. 9, 3152 (2018).","journal-title":"Front. Immunol."},{"key":"60195_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.immuni.2018.03.009","volume":"48","author":"DI Godfrey","year":"2018","unstructured":"Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P. & Rossjohn, J. Unconventional T Cell Targets for Cancer Immunotherapy. Immunity 48, 453\u2013473 (2018).","journal-title":"Immunity"},{"key":"60195_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fimmu.2018.00384","volume":"9","author":"BJ Wolf","year":"2018","unstructured":"Wolf, B. J., Choi, J. E. & Exley, M. A. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy. Front. Immunol. 9, 384 (2018).","journal-title":"Front. Immunol."},{"key":"60195_CR24","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/eji.201142043","volume":"42","author":"A Rossignol","year":"2012","unstructured":"Rossignol, A. et al. Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients. Eur. J. Immunol. 42, 1870\u20131875 (2012).","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"60195_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/path.4779","volume":"240","author":"Sara Basbous","year":"2016","unstructured":"Basbous, S. et al. The Rho\/ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia. J. Pathol. https:\/\/doi.org\/10.1002\/path.4779 (2016).","journal-title":"The Journal of Pathology"},{"key":"60195_CR26","doi-asserted-by":"crossref","unstructured":"Barbarin, A. et al. Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases. Front. Immunol. 8 (2017).","DOI":"10.3389\/fimmu.2017.00316"},{"key":"60195_CR27","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/eji.201545539","volume":"45","author":"F Jacomet","year":"2015","unstructured":"Jacomet, F. et al. Evidence for eomesodermin-expressing innate-like CD8(+) KIR\/NKG2A(+) T cells in human adults and cord blood samples. Eur. J. Immunol. 45, 1926\u20131933 (2015).","journal-title":"Eur. J. Immunol."},{"key":"60195_CR28","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3389\/fimmu.2016.00688","volume":"7","author":"F Jacomet","year":"2017","unstructured":"Jacomet, F. et al. The Hypothesis of the Human iNKT\/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia. Front. Immunol. 7, 688 (2017).","journal-title":"Front. Immunol."},{"issue":"1","key":"60195_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjh.15858","volume":"186","author":"Emilie Cayssials","year":"2019","unstructured":"Cayssials, E. et al. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br. J. Haematol. https:\/\/doi.org\/10.1111\/bjh.15858 (2019).","journal-title":"British Journal of Haematology"},{"key":"60195_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/ni.1898","volume":"11","author":"MA Weinreich","year":"2010","unstructured":"Weinreich, M. A., Odumade, O. A., Jameson, S. C. & Hogquist, K. A. T cells expressing the transcription factor PLZF regulate the development of memory-like CD8+ T cells. Nat. Immunol. 11, 709\u2013716 (2010).","journal-title":"Nat. Immunol."},{"key":"60195_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1084\/jem.20101527","volume":"208","author":"D Lai","year":"2011","unstructured":"Lai, D. et al. KLF13 sustains thymic memory-like CD8+ T cells in BALB\/c mice by regulating IL-4\u2013generating invariant natural killer T cells. J. Exp. Med. 208, 1093\u20131103 (2011).","journal-title":"J. Exp. Med."},{"key":"60195_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1084\/jem.20131560","volume":"211","author":"C Daussy","year":"2014","unstructured":"Daussy, C. et al. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J. Exp. Med. 211, 563\u2013577 (2014).","journal-title":"J. Exp. Med."},{"key":"60195_CR33","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/ni.2731","volume":"14","author":"YJ Lee","year":"2013","unstructured":"Lee, Y. J., Holzapfel, K. L., Zhu, J., Jameson, S. C. & Hogquist, K. A. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat. Immunol. 14, 1146\u20131154 (2013).","journal-title":"Nat. Immunol."},{"key":"60195_CR34","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1016\/j.celrep.2019.05.012","volume":"27","author":"J-Y Park","year":"2019","unstructured":"Park, J.-Y., DiPalma, D. T., Kwon, J., Fink, J. & Park, J.-H. Quantitative Difference in PLZF Protein Expression Determines iNKT Lineage Fate and Controls Innate CD8 T Cell Generation. Cell Rep. 27, 2548\u20132557.e4 (2019).","journal-title":"Cell Rep."},{"key":"60195_CR35","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3109\/10428194.2010.550074","volume":"52","author":"JJ Powers","year":"2011","unstructured":"Powers, J. J. et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk. Lymphoma 52, 668\u2013679 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"60195_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","volume":"85","author":"P Rohon","year":"2010","unstructured":"Rohon, P., Porkka, K. & Mustjoki, S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur. J. Haematol. 85, 387\u2013398 (2010).","journal-title":"Eur. J. Haematol."},{"key":"60195_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/imcb.12248","volume":"97","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. The peripheral differentiation of human natural killer T cells. Immunol. Cell Biol. 97, 586\u2013596 (2019).","journal-title":"Immunol. Cell Biol."},{"key":"60195_CR38","doi-asserted-by":"crossref","unstructured":"Knox, J. J., Cosma, G. L., Betts, M. R. & McLane, L. M. Characterization of T-Bet and Eomes in Peripheral Human Immune Cells. Front. Immunol. 5 (2014).","DOI":"10.3389\/fimmu.2014.00217"},{"key":"60195_CR39","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1182\/blood-2012-02-407163","volume":"120","author":"Y Yang","year":"2012","unstructured":"Yang, Y. et al. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 120, 4533\u20134543 (2012).","journal-title":"Blood"},{"key":"60195_CR40","doi-asserted-by":"publisher","first-page":"e27589","DOI":"10.4161\/onci.27589","volume":"3","author":"DB Lowe","year":"2014","unstructured":"Lowe, D. B. et al. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 3, e27589 (2014).","journal-title":"Oncoimmunology"},{"key":"60195_CR41","first-page":"5749","volume":"186","author":"HS Min","year":"2011","unstructured":"Min, H. S. et al. MHC class II-restricted interaction between thymocytes plays an essential role in the production of innate CD8+ T cells. J. Immunol. Baltim. Md 1950 186, 5749\u20135757 (2011).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"60195_CR42","first-page":"1429","volume":"182","author":"SC Morris","year":"2009","unstructured":"Morris, S. C. et al. Endogenously produced IL-4 nonredundantly stimulates CD8+ T cell proliferation. J. Immunol. Baltim. Md 1950 182, 1429\u20131438 (2009).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"60195_CR43","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/intimm\/dxl073","volume":"18","author":"N Ueda","year":"2006","unstructured":"Ueda, N. et al. CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4. Int. Immunol. 18, 1397\u20131404 (2006).","journal-title":"Int. Immunol."},{"key":"60195_CR44","doi-asserted-by":"publisher","first-page":"e1007456","DOI":"10.1371\/journal.ppat.1007456","volume":"15","author":"NS Baez","year":"2019","unstructured":"Baez, N. S. et al. Thymic expression of IL-4 and IL-15 after systemic inflammatory or infectious Th1 disease processes induce the acquisition of \u2018innate\u2019 characteristics during CD8+ T cell development. PLoS Pathog. 15, e1007456 (2019).","journal-title":"PLoS Pathog."},{"key":"60195_CR45","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1084\/jem.20110308","volume":"208","author":"AE Moran","year":"2011","unstructured":"Moran, A. E. et al. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208, 1279\u20131289 (2011).","journal-title":"J. Exp. Med."},{"key":"60195_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.leukres.2016.09.019","volume":"50","author":"S S\u00f6derlund","year":"2016","unstructured":"S\u00f6derlund, S. et al. Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. Leuk. Res. 50, 95\u2013103 (2016).","journal-title":"Leuk. Res."},{"key":"60195_CR47","first-page":"2434","volume":"197","author":"NP Goplen","year":"2016","unstructured":"Goplen, N. P. et al. IL-12 Signals through the TCR To Support CD8 Innate Immune Responses. J. Immunol. Baltim. Md 1950 197, 2434\u20132443 (2016).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"60195_CR48","first-page":"eaav2437","volume":"5","author":"MM Tu","year":"2019","unstructured":"Tu, M. M. et al. Targeting DDR2 enhances tumor response to anti-PD-1. immunotherapy. Sci. Adv. 5, eaav2437 (2019).","journal-title":"immunotherapy. Sci. Adv."},{"key":"60195_CR49","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s00018-018-2863-3","volume":"75","author":"G-T Yu","year":"2018","unstructured":"Yu, G.-T. et al. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma. Cell. Mol. Life Sci. CMLS 75, 4223\u20134234 (2018).","journal-title":"Cell. Mol. Life Sci. CMLS"},{"issue":"499","key":"60195_CR50","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"Katrin Mestermann","year":"2019","unstructured":"Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci. Transl. Med. 11 (2019).","journal-title":"Science Translational Medicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60195-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60195-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60195-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:41:34Z","timestamp":1670312494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60195-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60195"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60195-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3245"}}